Tạp chí Tim mạch học Việt Nam

Article detail

Article detail description

Home
BÀI TỔNG QUAN Issue: Số 109 TĂNG HUYẾT ÁP

Sodium glucose co-transporter 2 inhibition following acute myocardial infarction and in patients with type 2 diabetes mellitus with hypertension

Nguyễn Quan Đức Minh: Trường Đại học Y Dược Cần Thơ; Nguyễn Ngọc Vy Yến: Trường Đại học Y Dược Cần Thơ; Trần Kim Sơn: Trường Đại học Y Dược Cần Thơ;
Published: May 31, 2024
Views: 82

Abstract

Sodium-glucose cotransporter 2 inhibitors have been shown to improve cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes at high cardiovascular risk, and patients with chronic kidney disease. However, the effectiveness and safety of this group of drugs in patients with acute myocardial infarction are still unknown. Additionally, their ability to control blood pressure in patients with type 2 diabetes and hypertension remains to be determined.

References

1.
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147(8):e93-e621. doi:10.1161/CIR.0000000000001123
2.
Zhang Q, Zhou S, Liu L. Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis. Diabetol Metab Syndr. 2023;15(1):118. doi:10.1186/s13098-023-01092-z
3.
Cardiology ACo. EMPACT-MI: Empagliflozin Post MI Does Not Lower Risk of First HF Hospitalization, Death. 2024.
4.
Cardiology ACo. DAPA-MI: Dapagliflozin vs. Placebo in Patients With AMI. 2023.
5.
Butler J, Jones WS, Udell JA, et al. Empagliflozin after Acute Myocardial Infarction. N Engl J Med. 2024;390(16):1455-1466. doi:10.1056/NEJMoa2314051
6.
James S, Erlinge D, Storey RF, et al. Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction. Am Heart J. 2023;266:188-197. doi:10.1016/j.ahj.2023.08.008
7.
James S, Erlinge D, Storey RF, et al. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evid. 2024;3(2):EVIDoa2300286. doi:10.1056/EVIDoa2300286

Files

Article Views82
Document Views0
Downloads0
Section BÀI TỔNG QUAN
Issue Số 109
Category TĂNG HUYẾT ÁP